Towards Better Control in CKD: Improving Anemia Management

ANNA CE Satellite Symposium - New Orleans, Louisiana, October 17, 2004
Welcome, Introduction, and Program Overview
Moderators: Lesley C. Dinwiddie, MSN, RN, FNP, CNN; David B. Van Wyck, MD
Morbidity of Anemia in Patients with Chronic Kidney Disease
Joel D. Glickman, MD

Characteristics of Available Iron Products
David B. Van Wyck, MD

Managing Anemia Management
Michelle Turgeon, MSW
Questions and Answers
Speakers and moderators

Joel Glickman, MD, FACP
Pennsylvania Nephrology Associates
Farm Journal Building, Suite 100
230 W. Washington Square
Philadelphia, PA 19106

David Van Wyck, MD
Kidney Health Institute, LLC
6720 North Nanini Drive
Tucson, AZ 85704

Michelle Turgeon, MSW
Regional Director
Gambro Healthcare
201 Edgefield Road
North Augusta, SC 29841
This satellite symposium is sponsored by an unrestricted educational grant from American Regent Laboratories, Inc. This activity has been planned and produced in accordance with CE guidelines and policies. From a CE symposium held on October 17, 2004 at the American Nephrology Nurses' Association (ANNA) Fall Meeting in New Orleans, LA. This symposium was approved by ANNA. It was not part of the official ANNA Annual Meeting.
This activity has been awarded 1.5 contact hours by the American Nephrology Nurses Association (ANNA) which is accredited as a provider and approver of continuing education in nursing by the American Nurses Credentialing Center-Commission on Accreditation (ANCC-COA).
Posting Date: January, 2005
CE Credit Eligible Through: May, 2006
CE Credit Hours/Completion Time: 1.5
Target Audiences: Nurses, nurse practitioners, and other healthcare professionals who treat and manage patients with CKD.
Method of participation: Listen to the talk, read the PubMed abstracts linked to data slides and talk references, take the post-test, read the linked abstracts in the post-test answer feedback material.
After participating in this program, the participant should be able to:
  1. Describe the benefits of anemia management in chronic kidney disease (CKD).
  2. Outline the results of a U.S. clinical trial of iron sucrose and erythropoietin in the treatment of anemia in CKD.
  3. Appraise the characteristics of available parenteral iron products.
  4. Explain the critical role of the nephrology nurse in anemia management.
Speaker is a member of the Speakers Bureau for American Regent Laboratories Inc.

The CE policy and disclosure statements of the American Nephrology Nurses' Association are given in detail on the Symposium Home Page. The CE policy statements of HDCN are listed on this page.